DETROIT Two medical studies -- including one on hydroxychloroquine, the controversial antimalaria drug -- have been retracted after the authors said they no longer can vouch for the accuracy of the data. ORIGINAL STORY: New COVID-19 studies raise flags, under auditThe medical journal The Lancet retracted a large, widely publicized study about the use of hydroxychloroquine due to possible flaws in the research data. The World Health Organization had paused its trial of hydroxychloroquine after the Lancet study was published, but after conducting its own evaluation, that research has resumed. The executive group received this recommendation and endorsed the continuation of all arms of solidarity trial, including hydroxychloroquine.Medical experts emphasized the retraction does not mean hydroxychloroquine does or does not work for COVID-19 patients. Several other studies involving the drug are still ongoing.

Last week, Local 4 discussed a very large study that raised concerns about hydroxychloroquine’s safety in COVID-19 patients. ORIGINAL STORY: Recent findings on hydroxychloroquine as coronavirus (COVID-19) treatment not favorableFrom the beginning of the pandemic, there has been a tidal wave of research into all things COVID-19. Because some of that research has turned out to be flawed, there has been more focus on research published in reputable journals. The New England Journal of Medicine’s paper under review suggested the use of blood pressure medications did not have any effect on death rates in COVID-19. Local 4 will keep viewers and readers updated with results of the reviews of the studies.